Evidence map›Paper›PMID 26308766›Full record

ArticleCancer2015

Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.

Richard H Ko, Tamekia L Jones, David Radvinsky, Nathan Robison, Paul S Gaynon, Eduard H Panosyan, Ioannis A Avramis, Vassilios I Avramis, Joan Rubin, Lawrence J Ettinger and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Review
  10. Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Richard H KoChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
Tamekia L JonesDepartment of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
David RadvinskyState University of New York of New York Downstate Medical Center, Brooklyn New York.
Nathan RobisonChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
Paul S GaynonChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
Eduard H PanosyanDivision of Pediatric Hematology and Oncology, Harbor-University of California Los Angeles Medical Center, Torrance, California.
Ioannis A AvramisChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
Vassilios I AvramisChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
Joan RubinDepartment of Pediatrics, St. Peter's University Hospital, New Brunswick, New Jersey.
Lawrence J EttingerChildren's Oncology Group, Monrovia, California.
Nita L SeibelCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.
Girish DhallChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
University of Southern California · USChildren's Center · USChildren's Hospital of Los Angeles · USChildren's Oncology Group · USNational Cancer Institute · USSaint Peter's University Hospital · USSUNY Downstate Health Sciences University · USUniversity of California, Los Angeles · USUniversity of Tennessee Health Science Center · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5M
NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U10 CA98413-08NCI NIH HHS U10 CA98543-08
6 · The paper itself

Abstract

backgroundThe objectives of this study were to assess the incidence of clinical allergy and end-induction antiasparaginase (anti-ASNase) antibodies in children with high-risk acute lymphoblastic leukemia treated with pegylated (PEG) Escherichia coli ASNase and to determine whether they carry any prognostic significance.

methodsOf 2057 eligible patients, 1155 were allocated to augmented arms in which PEG ASNase replaced native ASNase postinduction. Erwinia chrysanthemi (Erwinia) ASNase could be used to replace native ASNase after allergy, if available. Allergy and survival data were complete for 990 patients. End-induction antibody titers were available for 600 patients.

resultsDuring the consolidation phase, 289 of 990 patients (29.2%) had an allergic reaction. There were fewer allergic reactions to Erwinia ASNase than to native ASNase (odds ratio, 4.33; P < .0001) or PEG ASNase (odds ratio, 3.08; P < .0001) only during phase 1 of interim maintenance. There was no significant difference in 5-year event-free survival (EFS) between patients who received PEG ASNase throughout the entire study postinduction versus those who developed an allergic reaction to PEG ASNase during consolidation phase and subsequently received Erwinia ASNase (80.8% ± 2.8% and 81.6% ± 3.8%, respectively; P = .66). Patients who had positive antibody titers postinduction were more likely to have an allergic reaction to PEG ASNase (odds ratio, 2.4; P < .001). The 5-year EFS rate between patients who had negative versus positive antibody titers (80% ± 2.6% and 77.7% ± 4.3%, respectively; P = .68) and between patients who did not receive any ASNase postconsolidation and those who received PEG ASNase throughout the study (P = .22) were significantly different.

conclusionsThe current results demonstrate differences in the incidence rates of toxicity between ASNase preparations but not in EFS. The presence of anti-ASNase antibodies did not affect EFS.

Indexed as

AntibodiesAntineoplastic AgentsAsparaginaseChildChild, PreschoolDickeya chrysanthemiDrug HypersensitivityEscherichia coliHumansInduction ChemotherapyInfantPolyethylene GlycolsPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival AnalysisTreatment OutcomeAntibodiesAntineoplastic AgentsAsparaginasePolyethylene Glycolsasparaginasechildhood acute lymphoblastic leukemiadrug hypersensitivitysurvival

Identifiers

PMID26308766
PMCPMC4795901
OpenAlexW1838641826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.